$INFU
InfuSystem Holdings, Inc

2021 Q4 Form 10-Q Financial Statement

#000162828021023378 Filed on November 15, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $26.52M $26.57M $25.13M
YoY Change 7.32% 5.74% 16.92%
Cost Of Revenue $11.21M $11.31M $10.00M
YoY Change 15.35% 13.05% 8.13%
Gross Profit $15.31M $15.26M $15.12M
YoY Change 2.11% 0.9% 23.57%
Gross Profit Margin 57.74% 57.43% 60.19%
Selling, General & Admin $12.51M $14.47M $10.78M
YoY Change -1.48% 34.23% 15.47%
% of Gross Profit 81.71% 94.86% 71.31%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $3.656M $3.740M $3.560M
YoY Change 3.48% 5.06% 202.46%
% of Gross Profit 23.88% 24.51% 23.54%
Operating Expenses $13.71M $15.61M $11.87M
YoY Change -1.79% 31.51% 12.24%
Operating Profit $1.602M -$351.0K $3.253M
YoY Change 54.78% -110.79% 95.61%
Interest Expense -$468.0K $270.0K $283.0K
YoY Change 97.47% -4.59% -42.01%
% of Operating Profit -29.21% 8.7%
Other Income/Expense, Net -$36.00K -$44.00K $8.000K
YoY Change 300.0% -650.0% -172.73%
Pretax Income $1.098M -$665.0K $2.978M
YoY Change 39.16% -122.33% 155.84%
Income Tax $711.0K -$217.0K $38.00K
% Of Pretax Income 64.75% 1.28%
Net Earnings $387.0K -$448.0K $2.940M
YoY Change -96.37% -115.24% 159.03%
Net Earnings / Revenue 1.46% -1.69% 11.7%
Basic Earnings Per Share -$0.02 $0.15
Diluted Earnings Per Share $17.42K -$0.02 $0.14
COMMON SHARES
Basic Shares Outstanding 20.65M shares 20.58M shares 20.18M shares
Diluted Shares Outstanding 20.58M shares 21.66M shares

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $186.0K $165.0K $1.939M
YoY Change -98.07% -91.49% -38.58%
Cash & Equivalents $186.0K $165.0K $1.939M
Short-Term Investments
Other Short-Term Assets $2.535M $2.151M $1.587M
YoY Change 5.54% 35.54% -1.12%
Inventory $3.939M $3.705M $3.973M
Prepaid Expenses
Receivables $15.41M $15.85M $13.93M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $22.07M $21.87M $21.43M
YoY Change -25.88% 2.05% 12.82%
LONG-TERM ASSETS
Property, Plant & Equipment $4.523M $4.426M $4.286M
YoY Change 5.28% 3.27% 50.65%
Goodwill $3.710M $3.710M
YoY Change
Intangibles $10.93M $11.93M $12.24M
YoY Change -2.21% -2.53% -26.01%
Long-Term Investments
YoY Change
Other Assets $471.0K $207.0K $105.0K
YoY Change 348.57% 97.14% -46.15%
Total Long-Term Assets $75.52M $72.92M $58.88M
YoY Change 12.35% 23.84% -0.04%
TOTAL ASSETS
Total Short-Term Assets $22.07M $21.87M $21.43M
Total Long-Term Assets $75.52M $72.92M $58.88M
Total Assets $97.59M $94.79M $80.31M
YoY Change 0.61% 18.03% 3.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.862M $6.703M $6.936M
YoY Change 15.98% -3.36% -34.99%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $349.0K $336.0K $7.759M
YoY Change -96.3% -95.67% 10.7%
Total Short-Term Liabilities $12.90M $14.49M $19.70M
YoY Change -43.92% -26.49% -9.67%
LONG-TERM LIABILITIES
Long-Term Debt $32.75M $30.56M $27.03M
YoY Change 11.47% 13.04% -10.9%
Other Long-Term Liabilities $3.670M $3.287M $4.061M
YoY Change -5.02% -19.06% 2.97%
Total Long-Term Liabilities $32.75M $30.56M $27.03M
YoY Change 11.47% 13.04% -10.9%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.90M $14.49M $19.70M
Total Long-Term Liabilities $32.75M $30.56M $27.03M
Total Liabilities $49.31M $48.33M $50.92M
YoY Change -12.31% -5.08% -9.36%
SHAREHOLDERS EQUITY
Retained Earnings -$53.90M -$43.00M -$54.71M
YoY Change 22.41% -21.39% -12.01%
Common Stock $2.000K $2.000K $2.000K
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $48.27M $46.46M $29.39M
YoY Change
Total Liabilities & Shareholders Equity $97.59M $94.79M $80.31M
YoY Change 0.61% 18.03% 3.1%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income $387.0K -$448.0K $2.940M
YoY Change -96.37% -115.24% 159.03%
Depreciation, Depletion And Amortization $3.656M $3.740M $3.560M
YoY Change 3.48% 5.06% 202.46%
Cash From Operating Activities $3.711M $5.791M $8.406M
YoY Change -51.25% -31.11% 61.19%
INVESTING ACTIVITIES
Capital Expenditures -$6.404M -$4.975M -$3.357M
YoY Change 56.42% 48.2% -60.63%
Acquisitions
YoY Change
Other Investing Activities $777.0K $551.0K $2.899M
YoY Change -11.9% -80.99% 219.98%
Cash From Investing Activities -$5.627M -$4.424M -$458.0K
YoY Change 75.19% 865.94% -93.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.937M -1.366M -6.491M
YoY Change -41.46% -78.96% -268.12%
NET CHANGE
Cash From Operating Activities 3.711M 5.791M 8.406M
Cash From Investing Activities -5.627M -4.424M -458.0K
Cash From Financing Activities 1.937M -1.366M -6.491M
Net Change In Cash 21.00K 1.000K 1.457M
YoY Change -99.73% -99.93% 0.14%
FREE CASH FLOW
Cash From Operating Activities $3.711M $5.791M $8.406M
Capital Expenditures -$6.404M -$4.975M -$3.357M
Free Cash Flow $10.11M $10.77M $11.76M
YoY Change -13.59% -8.48% -14.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001337013
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35020
dei Entity Registrant Name
EntityRegistrantName
INFUSYSTEM HOLDINGS, INC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-3341405
dei Entity Address Address Line1
EntityAddressAddressLine1
3851 West Hamlin Road
dei Entity Address City Or Town
EntityAddressCityOrTown
Rochester Hills
dei Entity Address State Or Province
EntityAddressStateOrProvince
MI
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20649447 shares
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
48309
dei City Area Code
CityAreaCode
248
dei Local Phone Number
LocalPhoneNumber
291-1210
dei Trading Symbol
TradingSymbol
INFU
dei Security Exchange Name
SecurityExchangeName
NYSEAMER
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
165000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9648000 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15845000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
14720000 USD
CY2021Q3 us-gaap Inventory Net
InventoryNet
3705000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
3001000 USD
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
2151000 USD
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2402000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
21866000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
29771000 USD
CY2021Q3 infu Medical Equipment Held For Sale Or Rental
MedicalEquipmentHeldForSaleOrRental
1540000 USD
CY2020Q4 infu Medical Equipment Held For Sale Or Rental
MedicalEquipmentHeldForSaleOrRental
1603000 USD
CY2021Q3 infu Medical Equipment In Rental Service Net Of Accumulated Depreciation
MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation
36431000 USD
CY2020Q4 infu Medical Equipment In Rental Service Net Of Accumulated Depreciation
MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation
35611000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4426000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4296000 USD
CY2021Q3 us-gaap Goodwill
Goodwill
3710000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
0 USD
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
11928000 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
11177000 USD
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3859000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4461000 USD
CY2021Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
10819000 USD
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
9967000 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
207000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
105000 USD
CY2021Q3 us-gaap Assets
Assets
94786000 USD
CY2020Q4 us-gaap Assets
Assets
96991000 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6703000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6779000 USD
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
336000 USD
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
9423000 USD
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7446000 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
6795000 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
14485000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22997000 USD
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
30559000 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
29378000 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3287000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3864000 USD
CY2021Q3 us-gaap Liabilities
Liabilities
48331000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
56239000 USD
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24125687 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20607198 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23816193 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20297704 shares
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
2000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
2000 USD
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
89385000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
84785000 USD
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
70000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-43002000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44035000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
46455000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
40752000 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
94786000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
96991000 USD
CY2021Q3 us-gaap Revenues
Revenues
26566000 USD
CY2020Q3 us-gaap Revenues
Revenues
25125000 USD
us-gaap Revenues
Revenues
75863000 USD
us-gaap Revenues
Revenues
72677000 USD
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
11308000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
10003000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
30979000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
28914000 USD
CY2021Q3 us-gaap Gross Profit
GrossProfit
15258000 USD
CY2020Q3 us-gaap Gross Profit
GrossProfit
15122000 USD
us-gaap Gross Profit
GrossProfit
44884000 USD
us-gaap Gross Profit
GrossProfit
43763000 USD
CY2021Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
10000 USD
CY2020Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
11000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-99000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
534000 USD
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1125000 USD
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1075000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3264000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3225000 USD
CY2021Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2908000 USD
CY2020Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2196000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7964000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7263000 USD
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11566000 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8587000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
32537000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24949000 USD
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
15609000 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
11869000 USD
us-gaap Operating Expenses
OperatingExpenses
43666000 USD
us-gaap Operating Expenses
OperatingExpenses
35971000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-351000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
1218000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
3253000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
7792000 USD
CY2021Q3 us-gaap Interest Expense
InterestExpense
270000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
283000 USD
us-gaap Interest Expense
InterestExpense
909000 USD
us-gaap Interest Expense
InterestExpense
1018000 USD
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-44000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-150000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-20000 USD
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-665000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2978000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
159000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
6754000 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-217000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
38000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-874000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
92000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-448000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
2940000 USD
us-gaap Net Income Loss
NetIncomeLoss
1033000 USD
us-gaap Net Income Loss
NetIncomeLoss
6662000 USD
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.33
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.31
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20577886 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20179056 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20468842 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20060416 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20577886 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21663414 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21995216 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21637481 shares
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-448000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
2940000 USD
us-gaap Net Income Loss
NetIncomeLoss
1033000 USD
us-gaap Net Income Loss
NetIncomeLoss
6662000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent
41000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent
0 USD
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent
93000 USD
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent
0 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent
10000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent
0 USD
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent
23000 USD
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent
0 USD
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-417000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2940000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1103000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6662000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
26202000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
0 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
659000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
116000 USD
CY2020Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
528000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
2940000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
29389000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
44700000 USD
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
38000 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1955000 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
179000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
31000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-448000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
46455000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
22334000 USD
us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
0 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1222000 USD
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
190000 USD
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1269000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
250000 USD
us-gaap Net Income Loss
NetIncomeLoss
6662000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
29389000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
40752000 USD
us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
431000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4962000 USD
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
348000 USD
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1141000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
70000 USD
us-gaap Net Income Loss
NetIncomeLoss
1033000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
46455000 USD
us-gaap Net Income Loss
NetIncomeLoss
1033000 USD
us-gaap Net Income Loss
NetIncomeLoss
6662000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-99000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
534000 USD
us-gaap Depreciation
Depreciation
7705000 USD
us-gaap Depreciation
Depreciation
7267000 USD
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
848000 USD
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
150000 USD
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
1588000 USD
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
2949000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3264000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3225000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
132000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
13000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
4962000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1222000 USD
infu Payments To Acquire Medical Equipment
PaymentsToAcquireMedicalEquipment
11955000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
607000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
865000 USD
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
2214000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-875000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
16000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-217000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1490000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
630000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1074000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-251000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-75000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
102000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
114000 USD
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
-513000 USD
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
-869000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
14605000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
12668000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
7650000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 USD
infu Payments To Acquire Medical Equipment
PaymentsToAcquireMedicalEquipment
9645000 USD
us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
35458000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
61654000 USD
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
3870000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15688000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8950000 USD
us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
69306000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
31861000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
386000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1141000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1269000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
779000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
190000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
250000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-8400000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4426000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9483000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-708000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9648000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2647000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
165000 USD
us-gaap Business Combination Consideration Transferred Liabilities Incurred
BusinessCombinationConsiderationTransferredLiabilitiesIncurred
750000 USD
us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
8727000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1939000 USD
us-gaap Basis Of Accounting
BasisOfAccounting
Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies<div style="margin-top:12pt;padding-right:7.2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The terms “InfuSystem”, the “Company”, “we”, “our” and “us” are used herein to refer to InfuSystem Holdings, Inc. and its subsidiaries. InfuSystem is a leading provider of infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, and other sites of care. The Company provides products and services to hospitals, oncology practices and facilities and other alternative site health care providers. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support, and also operates pump service and repair Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and notes required by U.S. Generally Accepted Accounting Principles (“GAAP”) for complete financial statements. The accompanying unaudited condensed consolidated financial statements include all adjustments, composed of normal recurring adjustments, considered necessary by management to fairly state the Company’s results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the SEC on March 22, 2021.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The unaudited condensed consolidated financial statements are prepared in conformity with GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. The Company believes that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Derivatives Accounting Policy</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes all derivative financial instruments as cash flow hedges which are shown as either assets or liabilities on the Company’s consolidated balance sheets at fair value. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in fair value of the derivative is recorded to accumulated other comprehensive income (“AOCI”) in the consolidated balance sheets. The underlying hedge transaction is realized when the interest payments on debt are accrued; the applicable amount of gain or loss included in AOCI is reclassified into earnings in the consolidated statements of operations on the same line as the gain or loss on the hedged item attributable to the hedged risk. The cash flows from derivatives are classified as operating activities.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company maintains a policy of requiring that all derivative instruments be governed by an International Swaps and Derivatives Association Master Agreement and settles on a net basis.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair values of the Company’s derivative financial instruments are categorized as Level 2 of the fair value hierarchy as the values are derived using the market approach based on observable market inputs including quoted prices of similar instruments and interest rate forward curves.</span></div>
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
7650000 USD
infu Working Capital
WorkingCapital
327000 USD
CY2021Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
727000 USD
CY2021Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
74000 USD
CY2021Q3 infu Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Medical Equipment Held For Sale Or Rental
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalEquipmentHeldForSaleOrRental
40000 USD
CY2021Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
161000 USD
CY2021Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
4015000 USD
CY2021Q3 us-gaap Goodwill
Goodwill
3710000 USD
CY2021Q3 infu Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Right Of Use Asset
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset
288000 USD
CY2021Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Capital Lease Obligation
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation
288000 USD
CY2021Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
8727000 USD
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
200000 USD
CY2021Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
4015000 USD
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P11Y2M12D
CY2021Q3 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
26566000 USD
CY2020Q3 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
25731000 USD
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
76633000 USD
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
75270000 USD
CY2021Q3 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-373000 USD
CY2020Q3 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
2691000 USD
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
1268000 USD
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
6120000 USD
CY2021Q3 us-gaap Revenues
Revenues
26566000 USD
CY2020Q3 us-gaap Revenues
Revenues
25125000 USD
us-gaap Revenues
Revenues
75863000 USD
us-gaap Revenues
Revenues
72677000 USD
CY2021Q3 infu Medical Equipment Held For Sale Or Rental Gross
MedicalEquipmentHeldForSaleOrRentalGross
1592000 USD
CY2020Q4 infu Medical Equipment Held For Sale Or Rental Gross
MedicalEquipmentHeldForSaleOrRentalGross
1636000 USD
CY2021Q3 infu Medical Equipment For Sale Or Rental Reserve
MedicalEquipmentForSaleOrRentalReserve
52000 USD
CY2020Q4 infu Medical Equipment For Sale Or Rental Reserve
MedicalEquipmentForSaleOrRentalReserve
33000 USD
CY2021Q3 infu Medical Equipment Held For Sale Or Rental
MedicalEquipmentHeldForSaleOrRental
1540000 USD
CY2020Q4 infu Medical Equipment Held For Sale Or Rental
MedicalEquipmentHeldForSaleOrRental
1603000 USD
CY2021Q3 infu Medical Equipment In Rental Services Gross
MedicalEquipmentInRentalServicesGross
88107000 USD
CY2020Q4 infu Medical Equipment In Rental Services Gross
MedicalEquipmentInRentalServicesGross
83411000 USD
CY2021Q3 infu Medical Equipment In Rental Services Reserve
MedicalEquipmentInRentalServicesReserve
1356000 USD
CY2020Q4 infu Medical Equipment In Rental Services Reserve
MedicalEquipmentInRentalServicesReserve
893000 USD
CY2021Q3 infu Medical Equipment In Rental Services Accumulated Depreciation
MedicalEquipmentInRentalServicesAccumulatedDepreciation
50320000 USD
CY2020Q4 infu Medical Equipment In Rental Services Accumulated Depreciation
MedicalEquipmentInRentalServicesAccumulatedDepreciation
46907000 USD
CY2021Q3 infu Medical Equipment In Rental Service Net Of Accumulated Depreciation
MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation
36431000 USD
CY2020Q4 infu Medical Equipment In Rental Service Net Of Accumulated Depreciation
MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation
35611000 USD
CY2021Q3 infu Medical Equipment Net
MedicalEquipmentNet
37971000 USD
CY2020Q4 infu Medical Equipment Net
MedicalEquipmentNet
37214000 USD
CY2021Q3 infu Depreciation Expense Related To Medical Equipment
DepreciationExpenseRelatedToMedicalEquipment
2400000 USD
infu Depreciation Expense Related To Medical Equipment
DepreciationExpenseRelatedToMedicalEquipment
7000000 USD
CY2020Q3 infu Depreciation Expense Related To Medical Equipment
DepreciationExpenseRelatedToMedicalEquipment
2300000 USD
infu Depreciation Expense Related To Medical Equipment
DepreciationExpenseRelatedToMedicalEquipment
6700000 USD
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8070000 USD
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3644000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4426000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7275000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2979000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4296000 USD
CY2021Q3 us-gaap Depreciation Nonproduction
DepreciationNonproduction
200000 USD
us-gaap Depreciation Nonproduction
DepreciationNonproduction
700000 USD
CY2020Q3 us-gaap Depreciation Nonproduction
DepreciationNonproduction
200000 USD
us-gaap Depreciation Nonproduction
DepreciationNonproduction
600000 USD
CY2021Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2000000 USD
CY2021Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2000000 USD
CY2020Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2000000 USD
CY2020Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2000000 USD
CY2021Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
53802000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
41874000 USD
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
11928000 USD
CY2020Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
49787000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
38610000 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
11177000 USD
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1100000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3300000 USD
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1100000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3200000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
998000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
2494000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
990000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
990000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
810000 USD
CY2021Q3 infu Amortization Expense Year Five And Thereafter
AmortizationExpenseYearFiveAndThereafter
3646000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
9928000 USD
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
188000 USD
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
222000 USD
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
0 USD
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
0 USD
CY2021Q3 infu Long Term Debt Maturities Repayments Of Principal Year Four And Thereafter
LongTermDebtMaturitiesRepaymentsOfPrincipalYearFourAndThereafter
30804000 USD
CY2021Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
31214000 USD
CY2021Q3 infu Longterm Debt Gross Current
LongtermDebtGrossCurrent
410000 USD
CY2021Q3 infu Long Term Debt Gross Noncurrent
LongTermDebtGrossNoncurrent
30804000 USD
CY2021Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
31214000 USD
CY2020Q4 infu Longterm Debt Gross Current
LongtermDebtGrossCurrent
9440000 USD
CY2020Q4 infu Long Term Debt Gross Noncurrent
LongTermDebtGrossNoncurrent
29427000 USD
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
38867000 USD
CY2021Q3 infu Unamortized Debt Issuance Expense Current
UnamortizedDebtIssuanceExpenseCurrent
74000 USD
CY2021Q3 infu Unamortized Debt Issuance Expense Noncurrent
UnamortizedDebtIssuanceExpenseNoncurrent
245000 USD
CY2021Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
319000 USD
CY2020Q4 infu Unamortized Debt Issuance Expense Current
UnamortizedDebtIssuanceExpenseCurrent
17000 USD
CY2020Q4 infu Unamortized Debt Issuance Expense Noncurrent
UnamortizedDebtIssuanceExpenseNoncurrent
49000 USD
CY2020Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
66000 USD
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
336000 USD
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
30559000 USD
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
30895000 USD
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
9423000 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
29378000 USD
CY2020Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1484358 shares
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
38801000 USD
CY2021Q3 us-gaap Interest Expense
InterestExpense
300000 USD
us-gaap Interest Expense
InterestExpense
900000 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-200000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-900000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-448000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
2940000 USD
us-gaap Net Income Loss
NetIncomeLoss
1033000 USD
us-gaap Net Income Loss
NetIncomeLoss
6662000 USD
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20577886 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20179056 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20468842 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20060416 shares
CY2021Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1526374 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1577065 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20577886 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21663414 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21995216 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21637481 shares
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.33
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.31
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
300000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
100000 shares
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
100000 shares
CY2021Q2 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
20000000 USD
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
302000 USD
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
410000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
998000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
1238000 USD
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
65000 USD
CY2020Q3 us-gaap Variable Lease Cost
VariableLeaseCost
64000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
180000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
253000 USD
CY2021Q3 us-gaap Lease Cost
LeaseCost
367000 USD
CY2020Q3 us-gaap Lease Cost
LeaseCost
474000 USD
us-gaap Lease Cost
LeaseCost
1178000 USD
us-gaap Lease Cost
LeaseCost
1491000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
993000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
1130000 USD
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4264000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
288000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
260000 USD
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y3M18D
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y1M6D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.077
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.078
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
276000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1183000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
979000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
949000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
914000 USD
CY2021Q3 infu Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
2253000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6554000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2290000 USD
CY2020Q3 us-gaap Gross Profit
GrossProfit
15122000 USD
CY2021Q3 us-gaap Assets
Assets
94786000 USD
CY2021Q3 infu Revenues External
RevenuesExternal
26566000 USD
CY2021Q3 infu Revenues Internal
RevenuesInternal
0 USD
CY2021Q3 us-gaap Revenues
Revenues
26566000 USD
CY2021Q3 us-gaap Gross Profit
GrossProfit
15258000 USD
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
15609000 USD
CY2021Q3 us-gaap Interest Expense
InterestExpense
270000 USD
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-44000 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-217000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-448000 USD
CY2021Q3 us-gaap Assets
Assets
94786000 USD
CY2021Q3 infu Payments To Acquire Medical Equipment
PaymentsToAcquireMedicalEquipment
4702000 USD
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3740000 USD
CY2020Q3 infu Revenues External
RevenuesExternal
25125000 USD
CY2020Q3 infu Revenues Internal
RevenuesInternal
0 USD
CY2020Q3 us-gaap Revenues
Revenues
25125000 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
11869000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
283000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
38000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
2940000 USD
CY2020Q3 us-gaap Assets
Assets
80308000 USD
CY2020Q3 infu Payments To Acquire Medical Equipment
PaymentsToAcquireMedicalEquipment
3172000 USD
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3560000 USD
infu Revenues External
RevenuesExternal
75863000 USD
infu Revenues Internal
RevenuesInternal
0 USD
us-gaap Revenues
Revenues
75863000 USD
us-gaap Gross Profit
GrossProfit
44884000 USD
us-gaap Operating Expenses
OperatingExpenses
43666000 USD
us-gaap Interest Expense
InterestExpense
909000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-150000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-874000 USD
us-gaap Net Income Loss
NetIncomeLoss
1033000 USD
infu Payments To Acquire Medical Equipment
PaymentsToAcquireMedicalEquipment
9645000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
10969000 USD
infu Revenues External
RevenuesExternal
72677000 USD
infu Revenues Internal
RevenuesInternal
0 USD
us-gaap Revenues
Revenues
72677000 USD
us-gaap Gross Profit
GrossProfit
43763000 USD
us-gaap Operating Expenses
OperatingExpenses
35971000 USD
us-gaap Interest Expense
InterestExpense
1018000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-20000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
92000 USD
us-gaap Net Income Loss
NetIncomeLoss
6662000 USD
CY2020Q3 us-gaap Assets
Assets
80308000 USD
infu Payments To Acquire Medical Equipment
PaymentsToAcquireMedicalEquipment
11955000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
10492000 USD

Files In Submission

Name View Source Status
0001628280-21-023378-index-headers.html Edgar Link pending
0001628280-21-023378-index.html Edgar Link pending
0001628280-21-023378.txt Edgar Link pending
0001628280-21-023378-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
infu-20210930.htm Edgar Link pending
infu-20210930.xsd Edgar Link pending
infu-20210930xexx311.htm Edgar Link pending
infu-20210930xexx312.htm Edgar Link pending
infu-20210930xexx321.htm Edgar Link pending
infu-20210930xexx322.htm Edgar Link pending
infu-20210930_cal.xml Edgar Link unprocessable
infu-20210930_def.xml Edgar Link unprocessable
infu-20210930_g1.jpg Edgar Link pending
infu-20210930_htm.xml Edgar Link completed
infu-20210930_lab.xml Edgar Link unprocessable
infu-20210930_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending